TSPAN15 Antibody

What is TSPAN15 and why is it important in biological research?

TSPAN15 (Tetraspanin 15) is a member of the tetraspanin family of membrane proteins that organize protein complexes at the cell membrane. It has garnered significant research interest due to its essential role as a regulatory subunit of ADAM10 (A Disintegrin And Metalloproteinase 10), which functions as a "molecular scissor" that proteolytically cleaves the extracellular region from more than 100 substrate proteins. These substrates include critical proteins like Notch, amyloid precursor protein, cadherins, growth factors, and chemokines . TSPAN15 has been identified as one of six regulatory tetraspanins (TspanC8s) that modulate ADAM10 function, potentially determining its substrate specificity. Additionally, TSPAN15 has been implicated in cancer progression, with high expression associated with lymph node and distant metastasis in oesophageal squamous cell carcinoma . These roles make TSPAN15 an important target for both basic research and therapeutic investigations.

What types of TSPAN15 antibodies are available for research applications?

Several types of TSPAN15 antibodies are available for research applications, varying in host species, clonality, epitope targets, and conjugation status:

• Based on clonality: Primarily polyclonal antibodies are commercially available, derived from rabbit hosts .

• Based on target regions: Antibodies targeting specific amino acid regions, such as AA 115-235 or C-terminal regions of the TSPAN15 protein .

• Based on conjugation status:

  • Unconjugated primary antibodies for western blotting and immunoprecipitation

  • Fluorescently conjugated (e.g., FITC-conjugated) for immunofluorescence and flow cytometry

  • Enzyme-conjugated (e.g., HRP-conjugated) for ELISA and enhanced western blotting

  • Biotin-conjugated for signal amplification in various applications

• Based on reactivity: Antibodies with different species cross-reactivity profiles, with some specific to human TSPAN15 and others cross-reacting with mouse, rat, and other species .

The selection of the appropriate antibody depends on the specific research application, experimental design, and biological questions being addressed.

How should I select the appropriate TSPAN15 antibody for my research?

Selecting the appropriate TSPAN15 antibody requires consideration of multiple factors to ensure experimental success:

First, determine your experimental application. For Western blotting, unconjugated antibodies or HRP-conjugated antibodies may be most suitable. For immunofluorescence or flow cytometry, FITC-conjugated antibodies provide direct visualization . For co-immunoprecipitation studies to investigate TSPAN15 binding partners like ADAM10, select antibodies specifically validated for immunoprecipitation .

Second, consider the species reactivity required. If working with human samples or cell lines, human-specific TSPAN15 antibodies are sufficient. For comparative or translational studies involving animal models, cross-reactive antibodies that recognize TSPAN15 across multiple species would be beneficial .

Third, evaluate the target epitope. Some antibodies target specific regions like AA 115-235 or C-terminal regions of TSPAN15 . Research has shown that antibodies recognizing the large extracellular loop (LEL) of tetraspanins are particularly effective for most applications, though epitope accessibility may be affected by TSPAN15's interaction partners like ADAM10 .

Finally, review validation data for your specific application. The ideal antibody should have demonstrated specificity and sensitivity in applications similar to yours, with minimal background or cross-reactivity. Published literature showing successful use of particular antibody clones can provide confidence in your selection .

How can I optimize immunoprecipitation protocols using TSPAN15 antibodies?

Optimizing immunoprecipitation (IP) protocols with TSPAN15 antibodies requires careful consideration of several factors to ensure specific isolation of TSPAN15 and its binding partners:

First, lysis buffer selection is critical. Research has shown that a relatively stringent 1% digitonin lysis buffer is effective for preserving TSPAN15/ADAM10 interactions during immunoprecipitation . For standard IP protocols, consider using NP-40 lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, 1% NP-40, 0.5% deoxycholate, 0.1% SDS) as used successfully in TSPAN15-BTRC interaction studies .

For the immunoprecipitation procedure, incubate whole-cell extracts with anti-TSPAN15 antibodies (2-5 μg per mg of protein) at 4°C for 2 hours. Follow this by adding 100 μl of protein A/G agarose beads and incubating overnight at 4°C with gentle rotation. Perform at least three washing steps with PBS to remove non-specific binding. For more stringent washing, consider including low concentrations of detergent in the wash buffer .

When analyzing co-immunoprecipitated proteins, carefully select antibodies for Western blotting that recognize different epitopes than your IP antibody to avoid detection of the heavy and light chains of the precipitating antibody. For TSPAN15/ADAM10 interaction studies, anti-ADAM10 antibodies have been successfully used to detect co-immunoprecipitated ADAM10 after TSPAN15 IP .

To validate specificity, always include appropriate controls such as IgG isotype control antibodies processed in parallel with your TSPAN15 IP. Additionally, reciprocal IP (using antibodies against the suspected binding partner to pull down TSPAN15) can provide confirmatory evidence of specific interactions .

What are the best methods for detecting TSPAN15 expression in different cell and tissue types?

The optimal methods for detecting TSPAN15 expression vary depending on the sample type and research question. A comprehensive approach often combines multiple techniques:

For protein-level detection in cell lines and tissues, Western blotting provides semi-quantitative assessment of TSPAN15 expression. Use 20-40 μg of total protein lysate, separated on SDS-PAGE and transferred to PVDF membrane. Block with 5% non-fat milk in TBS-T, and incubate with anti-TSPAN15 primary antibody at 4°C overnight. After washing, apply HRP-conjugated secondary antibody and develop using enhanced chemiluminescence . Western blotting is particularly useful for comparing expression levels across different samples and validating antibody specificity.

Immunofluorescence microscopy offers spatial information about TSPAN15 localization. Research has demonstrated that TSPAN15 co-localizes with ADAM10 on the cell surface . For fixed cells, use 4% paraformaldehyde fixation followed by permeabilization with 0.1% Triton X-100. For membrane proteins like TSPAN15, gentle permeabilization is crucial to preserve membrane structure. FITC-conjugated TSPAN15 antibodies enable direct visualization, while unconjugated antibodies require fluorophore-labeled secondary antibodies .

Flow cytometry provides quantitative analysis of TSPAN15 expression at the single-cell level. Surface staining protocols using FITC-conjugated anti-TSPAN15 antibodies have been successfully employed to assess binding competition between different TSPAN15 antibodies . This approach is valuable for heterogeneous cell populations or when sorting TSPAN15-positive cells.

For tissue samples, immunohistochemistry (IHC) can reveal the distribution and expression patterns of TSPAN15. TSPAN15 IHC has been used to correlate expression with clinical parameters in cancer tissues . Standard IHC protocols with antigen retrieval steps are appropriate, typically using DAB (3,3'-diaminobenzidine) for visualization.

At the mRNA level, quantitative RT-PCR provides sensitive detection of TSPAN15 transcript abundance, complementing protein-level analyses and revealing transcriptional regulation patterns.

How can I validate the specificity of a TSPAN15 antibody for my experimental system?

Validating TSPAN15 antibody specificity is crucial for ensuring reliable experimental results. A comprehensive validation approach should include several complementary strategies:

First, perform Western blotting using positive and negative control samples. Cell lines with known TSPAN15 expression serve as positive controls, while TSPAN15-knockout cells provide the ideal negative control. A specific antibody will show a single band of the expected molecular weight (approximately 31 kDa for TSPAN15) in positive controls and no band in knockout cells. Comparing the banding pattern across multiple cell types with varying TSPAN15 expression levels can further confirm specificity .

Second, employ genetic validation approaches. Test the antibody in TSPAN15-knockout cell lines created using CRISPR-Cas9 or similar gene editing technologies. Alternatively, use siRNA or shRNA to knockdown TSPAN15 expression and confirm corresponding reduction in antibody signal. Conversely, overexpression of TSPAN15 should increase antibody signal proportionally . The search results mention lentiviral constructs for both TSPAN15 overexpression and knockdown that could be used for such validation .

Third, evaluate species cross-reactivity if relevant to your research. The search results indicate that many TSPAN15 antibodies are human-specific and do not detect mouse Tspan15 by Western blotting . This species specificity can be leveraged as another validation approach using samples from different species.

Fourth, perform epitope mapping to confirm antibody binding specificity. Research has successfully used chimeric constructs with mouse/human Tspan15 sequences to identify critical binding residues for antibodies. This approach revealed that changes in the FSV sequence significantly affected antibody recognition .

Finally, consider using orthogonal detection methods that don't rely on antibody recognition, such as mass spectrometry or RNA-level detection with RT-PCR, to correlate with antibody-based detection results.

How can TSPAN15 antibodies be used to study the TSPAN15-ADAM10 functional complex?

TSPAN15 antibodies provide powerful tools for investigating the TSPAN15-ADAM10 functional complex through multiple sophisticated approaches:

Co-immunoprecipitation studies using TSPAN15 antibodies have demonstrated that ADAM10 is the principal Tspan15-interacting protein. Research shows that TSPAN15 antibodies effectively co-immunoprecipitate ADAM10 when using appropriate lysis conditions (such as 1% digitonin buffer) . This approach can be extended to study how various stimuli or inhibitors affect the formation or stability of the TSPAN15-ADAM10 complex.

Proximity ligation assays (PLA) can be performed using TSPAN15 and ADAM10 antibodies to visualize and quantify their interaction in situ. This technique provides spatial information about where in the cell the interaction occurs and can detect changes in complex formation under different experimental conditions.

Functional studies can employ TSPAN15 antibodies as potential inhibitors of the TSPAN15-ADAM10 scissor complex. Research has shown that two of four characterized TSPAN15 monoclonal antibodies impaired ADAM10/TSPAN15 activity . These antibodies can be used to distinguish the specific contributions of TSPAN15-ADAM10 complexes from other ADAM10-containing complexes in cellular processes.

Immunofluorescence co-localization studies with TSPAN15 and ADAM10 antibodies have confirmed that endogenous TSPAN15 and ADAM10 co-localize on the cell surface . This approach can be expanded to investigate how their co-localization changes during cellular processes like differentiation, migration, or in response to stimuli.

The dependence of TSPAN15 expression on ADAM10 can be studied using TSPAN15 antibodies in ADAM10-knockout or ADAM10-inhibited systems. Research has demonstrated that endogenous TSPAN15 expression requires ADAM10 in both cell lines and primary cells , suggesting a stabilizing relationship that can be further investigated using antibody-based detection methods.

What role does TSPAN15 play in cancer progression and how can antibodies help investigate this?

TSPAN15 has significant implications in cancer progression, particularly in oesophageal squamous cell carcinoma (OSCC), and TSPAN15 antibodies offer valuable tools for investigating these oncogenic functions:

Clinical correlation studies using TSPAN15 antibodies for immunohistochemistry have revealed that high TSPAN15 expression in OSCC tissues is significantly associated with lymph node and distant metastasis, advanced clinical stage, and poor prognosis . This finding positions TSPAN15 as a potential prognostic biomarker that could be detected using validated antibodies in patient samples.

Mechanistic investigations have employed TSPAN15 antibodies to elucidate molecular interactions driving cancer progression. Immunoprecipitation with TSPAN15 antibodies followed by mass spectrometry analysis identified BTRC (beta-transducin repeat containing E3 ubiquitin protein ligase) as a TSPAN15-interacting protein in OSCC cells . This interaction appears to be functionally significant in cancer progression and could be further explored using co-immunoprecipitation and co-localization studies with TSPAN15 antibodies.

Functional studies in cancer models can utilize TSPAN15 antibodies to monitor protein expression after genetic manipulation. For example, researchers have used lentiviral constructs to either overexpress or knock down TSPAN15 in cancer cell lines to study its effect on malignant behaviors . TSPAN15 antibodies provide a means to confirm successful manipulation and correlate protein levels with phenotypic changes.

The connection between TSPAN15 and ADAM10 in cancer is particularly interesting, as ADAM10 cleaves numerous substrates involved in cancer progression, including Notch, cadherins, and growth factors . TSPAN15 antibodies can help determine if the cancer-promoting effects of TSPAN15 are mediated through ADAM10 regulation, by monitoring their co-expression and co-localization in tumor samples.

Therapeutic exploration could potentially use TSPAN15 antibodies that impair ADAM10/TSPAN15 activity as starting points for developing targeted therapies against TSPAN15-expressing tumors. Characterizing the epitopes and inhibitory mechanisms of these antibodies would be crucial for such translational applications.

How do TSPAN15 antibodies help in understanding the relationship between TSPAN15 and other TspanC8 family members?

TSPAN15 antibodies provide critical tools for dissecting the distinct roles of TSPAN15 within the TspanC8 family and its relationship with other family members:

Specificity validation is fundamental when studying closely related protein families. TSPAN15 antibodies have been characterized for their ability to distinguish TSPAN15 from other TspanC8 members. Research using chimeric constructs with swapped large extracellular loops (LELs) between Tspan5 and Tspan15 demonstrated that TSPAN15 antibodies recognized Tspan15 LEL on a Tspan5 backbone (T5-LEL15) but not the reciprocal protein (T15-LEL5) . This specificity enables precise detection of TSPAN15 without cross-reactivity with other TspanC8 members.

Comparative expression analysis using specific antibodies for different TspanC8 members, including TSPAN15, allows researchers to map their tissue and cell-type distribution patterns. This approach helps identify contexts where specific TspanC8s predominate and potentially regulate ADAM10 differently.

Functional redundancy versus specificity can be investigated using TSPAN15 antibodies in combination with genetic manipulation of other TspanC8 members. For instance, researchers can use TSPAN15 antibodies to monitor whether TSPAN15 expression changes when other TspanC8s are knocked down, potentially revealing compensatory mechanisms within this family.

Structure-function relationships can be explored using epitope-mapped TSPAN15 antibodies. Research has identified critical residues for antibody binding, including the FSV sequence in the human TSPAN15 LEL . These insights, combined with structural modeling based on the crystal structure of related tetraspanin CD81, provide valuable information about the three-dimensional organization of TSPAN15 and how it might differ from other TspanC8 members.

Competition assays between different TspanC8s for ADAM10 binding can be studied using TSPAN15 antibodies in co-immunoprecipitation experiments. This approach can reveal whether TSPAN15 and other TspanC8s compete for a limited pool of ADAM10 or bind to distinct subpopulations, helping to test the hypothesis that ADAM10 functions as six distinct scissors depending on its TspanC8 partner .

What are common challenges when working with TSPAN15 antibodies and how can they be addressed?

Working with TSPAN15 antibodies presents several technical challenges that researchers should anticipate and address:

Epitope masking is a significant concern when detecting membrane proteins like TSPAN15, particularly due to its interaction with ADAM10. Research has shown that ADAM10 may mask epitopes on TSPAN15, complicating antibody binding . This challenge was cleverly addressed by developing antibodies using ADAM10-knockout cells expressing human TSPAN15 as immunogens, exposing epitopes that would normally be blocked . For researchers, using multiple antibodies recognizing different epitopes can help ensure detection even if some epitopes are masked in certain experimental conditions.

Membrane protein extraction requires careful consideration of detergent conditions. For TSPAN15, which forms complexes with ADAM10, lysis buffers containing 1% digitonin have proven effective for preserving protein-protein interactions during immunoprecipitation . For Western blotting, complete solubilization may require stronger detergents, but this could disrupt protein complexes. Testing multiple lysis conditions is advisable to optimize for your specific application.

Species cross-reactivity limitations exist for many TSPAN15 antibodies. Research has shown that antibodies developed against human TSPAN15 did not detect mouse Tspan15 by Western blotting . This specificity has been mapped to sequence differences between species, particularly in the FSV sequence . When working with animal models, carefully verify antibody cross-reactivity or select antibodies specifically validated for your species of interest.

Post-translational modifications and protein processing may affect antibody recognition. TSPAN15's function depends on its interaction with ADAM10, and research has shown that TSPAN15 expression requires ADAM10 , suggesting interdependent processing or stability. Antibodies may differently recognize mature versus immature forms of TSPAN15, potentially leading to inconsistent results across different detection methods.

Signal amplification may be necessary for detecting low-abundance TSPAN15. Consider using biotin-conjugated TSPAN15 antibodies followed by streptavidin-based detection systems , or employing tyramide signal amplification for immunohistochemistry and immunofluorescence applications.

How do I interpret contradictory results from different TSPAN15 antibodies?

Contradictory results from different TSPAN15 antibodies can be puzzling but understanding the possible causes and implementing systematic validation can help resolve discrepancies:

First, recognize that epitope differences significantly impact antibody behavior. TSPAN15 antibodies targeting different regions of the protein may yield different results because some epitopes might be accessible only in certain contexts. For instance, antibodies recognizing the large extracellular loop (LEL) may detect surface-expressed TSPAN15, while antibodies against intracellular domains might detect total protein pools . Map the epitopes of your antibodies and consider how protein conformation, complex formation (especially with ADAM10), or sample preparation might affect epitope accessibility.

Second, validate antibody specificity using genetic approaches. If one antibody detects a signal in TSPAN15-knockout cells while another doesn't, the former likely has nonspecific binding. Similarly, if signal reduction after TSPAN15 knockdown is observed with one antibody but not another, the responsive antibody is more likely to be specific . Overexpression systems can also help confirm that increased signal correlates with increased TSPAN15 expression.

Third, examine application-specific performance. Some antibodies work well for Western blotting but poorly for immunoprecipitation or immunofluorescence. The search results mention TSPAN15 antibodies with different application validations, including some specific for ELISA and immunofluorescence but not Western blotting . Test each antibody in your specific application and consider that contradictory results might reflect application-dependent performance rather than actual biological differences.

Fourth, consider post-translational modifications and protein isoforms. Different antibodies might preferentially recognize modified forms of TSPAN15 or specific isoforms. Since TSPAN15 expression depends on ADAM10 , antibodies might differently detect ADAM10-associated versus free TSPAN15.

Finally, implement orthogonal detection methods. When antibody-based approaches yield contradictory results, use non-antibody methods like mass spectrometry or mRNA detection to resolve discrepancies. For functional studies, genetic manipulation (overexpression or knockdown) coupled with phenotypic assays can help determine which antibody results correlate with functional outcomes.

What considerations are important when using TSPAN15 antibodies for quantitative analyses?

Quantitative analyses using TSPAN15 antibodies require careful attention to several methodological considerations:

Antibody affinity and dynamic range significantly impact quantification. For accurate quantification across samples with widely varying TSPAN15 expression levels, ensure your antibody maintains linear signal response throughout the expected concentration range. Perform standard curves using recombinant TSPAN15 protein or lysates from cells with defined TSPAN15 expression levels to establish the quantitative relationship between protein amount and signal intensity.

Normalization strategies are essential for comparative analyses. For Western blotting, housekeeping proteins like β-actin provide internal loading controls , though their expression may vary across tissues or experimental conditions. For immunohistochemistry, consider using tissue microarrays with control samples processed simultaneously to minimize batch effects. In flow cytometry, include calibration beads with known antibody binding capacity to convert fluorescence intensity to absolute molecule numbers.

Technical replication reduces measurement error. Perform at least three independent experiments with duplicate or triplicate technical replicates for each sample. This approach allows statistical assessment of measurement variability and increases confidence in observed differences between experimental groups.

Background correction is particularly important for membrane proteins like TSPAN15. In Western blotting, carefully select blocking conditions (5% non-fat milk in TBS-T has been used successfully) to minimize non-specific binding. For immunofluorescence and flow cytometry, include isotype control antibodies at the same concentration as TSPAN15 antibodies to establish background signal levels.

Epitope accessibility may vary across sample types or experimental conditions, affecting quantification. Since TSPAN15 forms complexes with ADAM10 , changes in complex formation might alter antibody binding without changing actual TSPAN15 expression. Using multiple antibodies recognizing different epitopes can help control for this variation.

Statistical analysis should account for the nature of the data. Western blot densitometry typically yields relative rather than absolute quantification and may show non-normal distribution. Consider appropriate statistical tests (parametric or non-parametric) based on data distribution, and report results with appropriate measures of central tendency and dispersion.

How are TSPAN15 antibodies being used to explore TSPAN15's role in Notch signaling regulation?

TSPAN15 antibodies are providing valuable insights into the relationship between TSPAN15 and Notch signaling regulation, an emerging area of research with significant implications:

The connection between TSPAN15 and Notch signaling stems from TSPAN15's role as a regulatory partner of ADAM10, which is a critical protease responsible for Notch receptor cleavage during signal activation . TSPAN15 antibodies enable the specific investigation of how this particular TspanC8 family member might differentially regulate ADAM10's activity toward Notch compared to other ADAM10 substrates.

Functional inhibition studies using TSPAN15 antibodies that impair ADAM10/TSPAN15 activity can help determine the specific contribution of TSPAN15-ADAM10 complexes to Notch processing. By comparing Notch activation in cells treated with these inhibitory antibodies versus isotype controls, researchers can isolate TSPAN15's role in the signaling pathway.

Co-localization analyses using fluorescently labeled TSPAN15 antibodies alongside Notch receptor antibodies can reveal spatial relationships between TSPAN15-ADAM10 complexes and Notch receptors at the cell surface. This approach can identify potential signaling microdomains and how they might be regulated during development or disease processes.

Proteolytic activity assays measuring Notch cleavage products in the presence or absence of TSPAN15, detected using TSPAN15 antibodies, can directly link TSPAN15 expression levels to Notch processing efficiency. These assays can be performed in cell lines with manipulated TSPAN15 expression or in samples from different tissues or disease states.

Background information in the search results indicates TSPAN15 may play a role in "positive regulation of Notch signaling pathway" , suggesting a specific regulatory function that can be further explored using TSPAN15 antibodies to monitor expression, localization, and interaction partners in Notch-dependent biological processes.

What is known about TSPAN15's role in extracellular vesicles and how can antibodies help study this function?

TSPAN15's presence in extracellular vesicles represents an intriguing aspect of its biology that can be effectively studied using appropriate antibodies:

The search results indicate that TSPAN15 is associated with "extracellular exosomes" , suggesting it may play a role in extracellular vesicle (EV) biology. Tetraspanins are known to be enriched in exosomes, and some family members (like CD9, CD63, and CD81) are commonly used as exosomal markers. TSPAN15 antibodies can help determine whether TSPAN15 serves similar functions or has unique roles in exosome biogenesis or cargo selection.

Immuno-isolation of TSPAN15-positive EVs can be performed using TSPAN15 antibodies conjugated to magnetic beads or other capture platforms. This approach allows selective enrichment of TSPAN15-containing EVs from complex biological fluids or cell culture supernatants, enabling detailed characterization of their cargo and functional properties.

Multi-parameter flow cytometry of EVs using fluorescently labeled TSPAN15 antibodies in combination with antibodies against other EV markers can help define subpopulations of EVs and their cellular origins. This approach requires high-sensitivity flow cytometers capable of detecting submicron particles but can provide valuable insights into EV heterogeneity.

Immunogold electron microscopy using TSPAN15 antibodies can precisely localize TSPAN15 within the EV membrane structure and determine whether it clusters with other proteins, potentially forming specialized membrane microdomains that might influence EV biogenesis or uptake by recipient cells.

Functional studies can employ TSPAN15 antibodies to track the transfer of TSPAN15-containing EVs between cells and investigate whether blocking TSPAN15 on EVs affects their cellular uptake or functional effects. Since TSPAN15 interacts with ADAM10 , it's possible that TSPAN15-positive EVs might transfer functional ADAM10 activity to recipient cells, a hypothesis that could be tested using TSPAN15 antibodies.

How can TSPAN15 antibodies contribute to developing potential cancer therapeutics?

TSPAN15 antibodies show promise as tools for developing cancer therapeutics through several research avenues:

Target validation studies using TSPAN15 antibodies have established TSPAN15 as a potential therapeutic target, particularly in oesophageal squamous cell carcinoma (OSCC) where high TSPAN15 expression correlates with lymph node and distant metastasis, advanced clinical stage, and poor prognosis . These findings provide a rationale for developing therapeutic strategies targeting TSPAN15 in cancer.

Inhibitory antibodies that impair ADAM10/TSPAN15 activity have already been identified . These antibodies could serve as starting points for developing therapeutic candidates, as they demonstrate that antibody-mediated inhibition of TSPAN15 function is feasible. Further characterization of their inhibitory mechanisms and optimization of their properties (affinity, stability, etc.) could advance their therapeutic potential.

Antibody-drug conjugates (ADCs) represent another promising application. TSPAN15 antibodies could be conjugated to cytotoxic drugs for targeted delivery to TSPAN15-expressing cancer cells. The cell surface localization of TSPAN15 makes it an accessible target for ADCs, potentially enabling selective killing of cancer cells while sparing normal tissues with lower TSPAN15 expression.

Biomarker development using TSPAN15 antibodies could help identify patients most likely to benefit from TSPAN15-targeted therapies. Immunohistochemical staining of tumor biopsies with TSPAN15 antibodies could stratify patients based on TSPAN15 expression levels, supporting personalized treatment approaches.

Combination therapy strategies could be developed based on mechanistic insights gained from TSPAN15 antibody studies. For instance, the interaction between TSPAN15 and BTRC identified through immunoprecipitation with TSPAN15 antibodies suggests potential synergies between TSPAN15-targeted therapies and therapies targeting related signaling pathways, which could be explored in preclinical models.